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Abstract
Pre-eclampsia is a leading cause of maternal and perinatal morbidity and mortality world-
wide. The etiology is not clear, but an immune attack towards components of placenta or
fetus has been indicated. This involves activation of the complement system in the placenta.
We have previously described the presence of the complement-regulating protein salivary
scavenger and agglutinin (SALSA) in amniotic fluid. In this study we investigated the poten-
tial role of SALSA in pregnancy by analyzing its presence in amniotic fluid and placental tis-
sue during healthy and complicated pregnancies. SALSA levels in amniotic fluid increased
during pregnancy. Before 20 weeks of gestation the levels were slightly higher in patients
who later developed pre-eclampsia than in gestation age-matched controls. In the placenta
of pre-eclamptic patients syncytial damage is often followed by the formation of fibrinoid
structures. SALSA was found clustered into these fibrinoid structures in partial co-localiza-
tion with complement C1q and fibronectin. In vitro analysis showed direct protein binding of
SALSA to fibronectin. SALSA binds also to fibrin/fibrinogen but did not interfere with the
blood clotting process in vitro. Thus, in addition to antimicrobial defense and epithelial differ-
entiation, the data presented here suggest that SALSA, together with fibronectin and C1q,
may be involved in the containment of injured placental structures into fibrinoids.
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Introduction
Pregnancy introduces a temporary condition, where two humans co-exist, one inside the other.
During this period, fetus and placenta may express and secrete paternal antigens. Thus, this
symbiosis challenges the maternal immune defense system to develop tolerance to these new
antigens. Pre-eclampsia (PE) is a common pregnancy-related complication affecting 3% of all
pregnancies. It is the leading cause of maternal and perinatal morbidity and mortality world-
wide [1,2]. The etiology of PE is currently unclear. Many observations point towards the possi-
bility that an immune incompatibility between the feto-placental unit and the mother could be
involved. Similar factors could also contribute to other pregnancy complications such as intra-
uterine growth restriction (IUGR) and premature birth.
Specific characteristics of PE include intravascular inflammation with elevated levels of pro-
inflammatory cytokines in the maternal circulation, and endothelial cell activation and/or dys-
function [3–6]. In concert with these findings, PE is often accompanied by platelet and throm-
bin activation, leading to thrombocytopenia and a risk for intravascular coagulation [7]. A
prominent feature of PE is the activation of the coagulation cascade, e.g. through activation of
thrombin [8,9]. As a sign of both injury and activation of the coagulation cascade lesions
known as fibrinoids can be detected in the placenta and occasionally also in various organs of
the maternal body [10]. Fibrinoids are generally divided into two categories, matrix-type and
fibrin-type fibrinoids [11]. Matrix-type fibrinoid is generated by invading extravillous tropho-
blast cells. Fibrin-type fibrinoid resembles blood clots as seen in other tissues, and may be
deposited where blood flow is impaired or where the syncytiotrophoblast layer is injured or
interrupted [11]. Excessive syncytial damage with fibrinoid formation is a common feature of
complicated pregnancies. However, fibrinoids may also be observed in healthy placentas [11].
The complement system is an essential part of the innate immune defense system with well-
established functions in both the protection against invading pathogens as well as in waste dis-
posal of e.g. apoptotic and injured cell material. The complement system is composed of three
pathways initiated by binding of pattern recognition molecules, such as C1q (classical path-
way), mannose binding lectin (MBL) and ficolins (lectin pathway). The third (alternative)
pathway recognizes a wide variety of nonself structures and functions as an amplification loop
for complement activation initiated via other pathways [12,13]. During pregnancy there is a
general suppression of the immune system to protect the fetus. Under healthy conditions, the
immune system, including the complement system, is still able to clear injured and necrotic tis-
sues. However, in some cases malfunction of this process may occur and the deposition of this
material into fibrinoid clusters at the surface of placental villi and other sites could cause
inflammation. In time this may lead to endothelial-vascular disorders and a proinflammatory
state in the maternal circulation [14].
The salivary scavenger and agglutinin (SALSA), also known as gp340, salivary agglutinin
(SAG) and deleted in malignant brain tumor 1 (DMBT1) is a glycoprotein of 340 kDa (Gen-
bank accession no. BAA78577.1) [15–17]. SALSA belongs to an ancient family of scavenger
receptors, the scavenger receptor cysteine-rich (SRCR) protein family, identified by multiple
repeats of the highly conserved SRCR domains [18]. SALSA is produced by mucosal tissues
throughout the body. The protein is found to be associated with the epithelial layers in the
lung, mouth, trachea, gastrointestinal tract, vagina and skin [18–22]. However, studies have
found that SALSA is also expressed sporadically in the endothelial cells of cardiac capillaries
and in capillaries of skeletal muscle, at least in mice [23,24]. Several secreted forms of SALSA
have been found in body fluids lining the mucosal surfaces such as saliva, lacrimal fluid, pan-
creatic juice and as well in bronchoalveolar lavage [15,16,25,26]. We recently observed that
SALSA is very abundant in the infant intestine and amniotic fluid (AF) [27]. However, so far it
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has not been described in blood. Recent advances in the understanding of the physiological
function of SALSA point towards a role in both epithelial cell differentiation and innate immu-
nity [28].
The complement components C1q and MBL bind SALSA and through these interactions
SALSA has been shown to regulate complement activation in solution and on surfaces [29–31].
The pathogenesis of pregnancy complications, in particular PE, has been associated with a reg-
ulatory disturbance in immune responses and specifically in complement activation. We there-
fore decided to further localize the SALSA protein in healthy and complicated pregnancies.
Our approach aimed to elucidate the role of SALSA in pregnancy by measuring its levels in AF
samples from women with normal and complicated pregnancies, localizing the SALSA protein
in placenta and determining its related molecular targets and interaction partners in placental
lesions.
Materials and Methods
Amniotic fluid samples
AF was collected at the Department of Obstetrics and Gynecology, Helsinki University Hospi-
tal, Helsinki, Finland. Samples from second trimester (17.2 ± 2.5 gestational weeks) were origi-
nally collected for screening of fetal chromosomes or assessment of alpha-fetoprotein. All
karyotypes and alpha-fetoprotein levels were normal. Samples from second trimester are
referred to as early pregnancy. AF samples from the third trimester (term pregnancy) were col-
lected by amniocentesis for assessment of fetal lung maturity or during caesarean section from
women with PE (gestational week 34 ± 2.3, n = 6), IUGR (gestational week 34.2 ± 3.6, n = 15),
diabetes mellitus type 1 (DM, gestational week 36.9 ± 1.2, n = 19) or gestational diabetes melli-
tus (GDM, gestational week 36.5 ± 2.5, n = 17). Control AF samples from women with uncom-
plicated pregnancies (gestational week 39.4 ± 1.0, n = 14) were collected by needle aspiration
during an elective caesarean section made because of breech presentation or fetopelvic dispro-
portion. After collection the samples were immediately frozen and stored at– 20°C. All amni-
otic fluid samples were collected after informed written consent, and use of the samples was
approved by the Medical University Graz, ethical commission (26–132 ex 13/) and the ethical
committee of the Hospital District of Helsinki and Uusimaa (14149/E0/07).
Placental samples
Placental samples were obtained from different cohorts. The following paraffin-embedded tis-
sue samples were obtained from Medical University of Graz, Austria. First trimester placentas
were obtained after elective termination of pregnancy for social reasons (gestational weeks
8–11, n = 3). Early onset PE-placentas (gestational weeks 29–34, n = 10) and age-matched con-
trols (gestational weeks 29–34, n = 7) were obtained after caesarean section. Healthy term pla-
centas (gestational weeks 36–40, n = 5) were obtained after vaginal delivery. The use of
placental samples was approved by the Medical University Graz, ethical committee (26–132 ex
13/14). Frozen placental tissue from PE (gestational weeks 35.3 ± 3.7, n = 13) and healthy (ges-
tational weeks 39.7 ± 1.5, n = 10) pregnancies were obtained from the Finnish Genetics of Pre-
eclampsia Consortium (FINNPEC) cohort including individuals delivering at the Helsinki
University Central Hospital, Finland. PE and healthy women delivered both by caesarean sec-
tion and vaginal delivery. FINNPEC study protocol was approved by the coordinating ethical
committee of the Hospital District of Helsinki and Uusimaa (14149/E0/07). Detailed descrip-
tion of the cohort has been reported previously [14]. Individuals with multiple pregnancies,
maternal age<18 years or known autoimmune diseases were excluded. All subjects gave writ-
ten informed consents.
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Quantification of SALSA in AF by ELISA
To quantify the levels of SALSA, samples were diluted and coated directly onto Maxisorp plates
(Nunc, Denmark). SALSA purified from saliva was used as a protein concentration standard.
After coating, the plates were blocked with 5% nonfat milk in TBS/1 mM Ca2+. The plates were
washed with TBS/Ca2+ and 0.05% Tween-20 (TBS/Ca2+/Tween). SALSA levels were detected
using monoclonal anti-SALSA (Hyb 213–06, Bioporto, Denmark) diluted to 0.05 μg/ml and
HRP-conjugated rabbit anti-mouse antibodies (Jackson ImmunoResearch Laboratories, West
Grove, PA) diluted 1:10 000 in TBS/Ca. OPD tablets (Dako, Denmark) were used for develop-
ment and the color reaction was measured with an iEMS Reader MF (Labsystems, Espoo, Fin-
land) at an OD of 492 nm. For each sample a dilution series was made to ensure that the
readings were within the linear range. Measurements were based on a minimum of three sepa-
rate assays.
Immunohistochemistry
Sections of paraffin-embedded tissues (5 μm) were dried O/N at 45°C and subjected to stan-
dard de-paraffination followed by antigen retrieval treatment in a pressure cooker at pH 9,
120°C and 15 psi pressure. Sections were washed briefly in TBS/ 0.05% Tween and blocked in
UltraVision Hydrogen Peroxide Block (Thermo Fisher Scientific, Waltham, MA, USA) fol-
lowed by UltraVision Protein Block. The staining protocol followed manufacturer recommen-
dations of the kit UltraVision LP Large Volume Detection System (HRP Polymer Ready-To-
Use, Thermo Fisher Scientific) with few specifications. Briefly, sections were washed four times
in TBS/Tween. For incubation (30 min, 37°C) anti-SALSA (Hyb 213–06) was diluted to a final
concentration of 10 μg/ml in antibody diluent (Dako) followed by incubation with primary
antibody enhancer, HRP Polymer, 3-Amino-9-Ethylcarbazole (All ThermoFisher Scientific)
and finally counterstain by Mayer's hemalum followed by mounting by Aquatex (Merck,
Darmstadt, Germany).
Fluorescence microscopy and immunohistochemistry
Sections of paraffin-embedded tissues were prepared as above. Frozen sections (5 μm) of
healthy and PE placentas were prepared by cryosectioning and stored at -70°C. The sections
were then thawed and rinsed briefly in TBS/Ca2+ before use. The sections were blocked in TBS/
Ca2+ with 1% bovine serum albumin (BSA) for 30 min at 37°C in a humid chamber. Antibodies
were diluted in TBS/Ca2+/BSA and incubated 30 min at 37°C in a humid chamber. Between
incubations the sections were washed 3 × 5 min in TBS/Ca2+/BSA. Anti-SALSA was diluted to
10 μg/ml. For co-localization studies PBS/0.05% Tween was used for washes while polyclonal
rabbit anti-cellular fibronectin (ab299, Abcam, Cambridge, United Kingdom) and rabbit anti-
C1q (Dako) antibodies were used 1:1000 in DAKO antibody diluent and Alexa 488 labeled
goat anti-rabbit and Alexa 546 labeled goat anti-mouse antibodies (both Invitrogen, Oregon,
USA) were used at 1:300 dilutions in PBS. Classical and lectin pathway activation was investi-
gated by staining with polyclonal rabbit anti-C4c (Dako) and Alexa 488 labeled goat anti-rabbit
(Invitrogen) diluted 1:400 and 1:300 in PBS, respectively. Nuclei were stained with DAPI (Invi-
trogen, Molecular Probes, Eugene, Oregon, USA) diluted 1:2000 in PBS. Ex vivo SALSA bind-
ing was tested using AF as a biological source of SALSA. An overlay was performed with un-
diluted AF after initial blocking on frozen sections. Following this the antibodies were added as
described. After final incubation and wash, excess liquid was removed and a mounting liquid
was added. The sections were then immediately analyzed by fluorescence microscopy in Fin-
land: Olympus DP Manager (ver. 2.2.1.195) and Olympus DP Controller (version 2.2.1.227)
image capture softwares with Olympus BX51 fluorescence microscope camera, and in Austria:
SALSA in Pregnancy
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VIS Visiopharm Integrator System (version: 4.5.1.324) software for multichannel image acqui-
sition and Leica microscope with Olympus DP72 camera.
Effect of SALSA on coagulation
Basic coagulation assays such as Thrombin Time and Activated Prothrombin Time measure-
ments were performed as described [32]. In short, Thrombin Time measurements were per-
formed by adding 100 μl BC Thrombin reagent (Siemens, Germany) to 40 μl citrated plasma.
Citrated plasma was taken into 3.2% sodium citrate 9NC anti-coagulation tubes (Greiner Bio-
One, Kremsmünster, Austria) and separated by centrifugation at 2500×g. Coagulation time
was measured using a coagulometer. Activated Prothrombin Time measurements were per-
formed by mixing 50 μl Dade Actin FSL reagent (Siemens) with 50 μl citrated plasma. After a 3
min incubation, 50 μl 0.025 mol/l CaCl2 was added, and the coagulation time was measured
using a coagulometer. For both assays, SALSA was mixed with plasma in the fluid phase prior
to the start of coagulation at final concentrations of 0 μg/ml, 1 μg/ml, 3 μg/ml and 5 μg/ml.
The effect of surface coated SALSA on coagulation was tested in an assay modified from the
protocol published by Rose and Babensee [33]. SALSA was coated at 1 μg/ml on a Maxisorp
plate. 100 μl citrated plasma was heated to 37°C and added to wells coated with SALSA or wells
without SALSA. 100 μl BC Thrombin reagent was heated to 37°C and added to initiate coagula-
tion. OD405 measurements were made every 20s for 30 min using a FLUOstar optima reader
(BMG Labtech, Offenburg, Germany). The increase in absorbance corresponds to the develop-
ment of the clot.
SALSA binding to fibronectin
Binding of SALSA to human plasma fibronectin was tested in an ELISA setup. Maxisorp plates
were coated with 1, 5, or 10 μg/ml of human plasma fibronectin (Chemicon, CA, USA) in
Na2CO3-buffer, pH 9.6 O/N at 4°C. Plates were washed 3 times with 0.5 mMNaCl, 20 mM
Tris, 0.05% Tween 20, pH 7.4 (TTSB) and blocked with 3% BSA in TTSB. After 2 hours at RT
plates were washed and SALSA (1 μg/ml in TTSB + 0.1% BSA with or without 1mM Ca2+) was
added and incubated for 60 min, RT. Binding was detected using monoclonal anti-SALSA anti-
body Hyb 213–06 (0.4 μg/ml in TTSB/BSA/Ca2+) and HRP-conjugated rabbit anti-mouse anti-
bodies (1:10 000 in TBS/Ca2+). OPD tablets were used for development and the color reaction
was measured. Each experiment was performed three times.
Results
Amniotic fluid SALSA levels in normal and complicated pregnancies
In our previous study we observed SALSA in AF from healthy pregnancies by immunoblotting.
In an ELISA analysis the concentrations of SALSA ranged between 0–11.5 μg/ml (mean:
2.1 ± 3.7 μg/ml) [27]. To identify a possible role for SALSA in the pathogenesis of pregnancy
complications, SALSA levels were measured in AF from patients diagnosed with IUGR, PE,
GDM or DM and compared to healthy controls. Included in the analysis were additional sam-
ples taken at an early stage (before 20 weeks of gestation) from patients who later developed PE
compared to age-matched controls. Levels of SALSA were measured by ELISA. The overall
protein level of the AF is known to vary during the course of pregnancy. Thus, to make the
samples comparable, SALSA concentrations were related to total protein levels of the AF sam-
ples (Fig 1).
The pathological process of PE assumingly starts much earlier than the manifestation of
symptoms [34]. Comparison of the SALSA levels at an early stage and at term could provide
SALSA in Pregnancy
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information on the expression of SALSA during the maturation of the fetus and possible role
in PE. First, samples were collected from healthy pregnancies at an early stage (before gesta-
tional week 20, n = 18) and at term (n = 14) and SALSA levels were measured by ELISA (Fig
1). The concentration of SALSA in AF increased during the maturation of the fetus. The actual
measured concentrations increased from 0.7 (± 0.5) μg/ml in early pregnancy to 2.1 (± 1.6) μg/
ml at term (p<0.0006). The corresponding total protein levels in AF increased from 5.3 mg/ml
to 6.8 mg/ml (p<0.01). Thus, the relative SALSA level doubled from 0.15‰ to 0.3‰ of the
total protein amount (p<0.05). This was corroborated by a positive Spearman correlation test
between the relative SALSA levels and the gestational week at sampling with a correlation coef-
ficient of 0.348 (p<0.05).
As shown in Fig 1 we observed variations in SALSA levels in early pregnancy in both
patients who later developed PE and healthy controls. The concentrations of SALSA were
0.7 ± 0.5 μg/ml (n = 18) for the control group and 1.4 ± 1.4 μg/ml (n = 9) for the PE group
(p = 0.09). When the values were related to the total protein levels the values were 0.17 ± 1.8‰
for controls and 0.29 ± 0.29‰ for PE. These differences were not significant, but indicated a
trend towards increased levels of SALSA at an early time point of patients who later developed
PE. At term no differences were found between SALSA levels in healthy controls and PE
Fig 1. SALSA levels in the amniotic fluid (AF) from healthy and complicated pregnancies. SALSA was
measured by ELISA. SALSA levels are shown relative to the total protein amount. Comparing samples taken
before 20th week of gestation from women who at term were either pre-eclamptic (PE, n = 9) or healthy
(n = 18), we found a trend of higher SALSA levels in PE pregnancies. However the difference was not
significant (0.32‰ ± 0.3 vs. 0.17‰ ± 0.18, Students t-test: p = 0.18). When comparing SALSA levels in AF
from healthy term (n = 14) and PE (n = 6) pregnancies no significant differences between the groups were
found (Student’s t-test, p > 0.1 for all). SALSA levels in AF from healthy pregnancies before 20th week of
gestation (n = 18) and at delivery (n = 14) were shown to double from 0.17‰ ± 0.18 to 0.31‰ ± 0.21 of the
total protein amount (Student’s t-test: p < 0.05).
doi:10.1371/journal.pone.0147867.g001
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patients. SALSA levels were also investigated for patients with IUGR, DM and GDM, however
no differences were found.
Deposition of SALSA in placenta
AF is a unique body fluid, since it is only present during pregnancy. The same is true for the
placenta and the surrounding tissue. Complement component deposits have been found in the
placenta during pregnancy. In addition, an increased deposition was seen in complicated preg-
nancies, such as PE [14]. To analyze the possible role of SALSA in pregnancy we investigated
the presence and deposition of SALSA in the placenta (Fig 2).
In Fig 2 both healthy (panels A-D) and pre-eclamptic (panels E and F) placentas were inves-
tigated. We observed focal positive staining of SALSA in most placental tissue sections. More
detailed investigation of SALSA in the placenta revealed that SALSA is present in fibrinoid for-
mations at various locations in the placenta. Furthermore, a weaker but positive staining of
SALSA was also seen intracellularly in the syncytiotrophoblasts. The syncytiotrophoblast layer
of some villi stained more strongly than others, while the cytotrophoblasts were negative for
SALSA. The most abundant staining was observed in fibrinoids at the edges of the villous struc-
tures. Whenever the syncytiotrophoblast layer was damaged or breached SALSA-positive fibri-
noids were observed (Fig 2, panels A and B). In placentas of both healthy and PE pregnancies
necrotic villous structures were observed. Eventually these had become covered by SALSA-pos-
itive fibrinoids, leaving ghost-like formations of the original villi (Fig 2 panels C and E). Dis-
ruption of the syncytium may lead to an influx of maternal blood into the fetal side of the
placenta. This maternal blood flow may separate the damaged syncytiotrophoblast layer from
its basement membrane and fibrinoid may be deposited in between the two layers. These ring-
shaped structures were also positive for SALSA (Fig 2 panels D and F). The SALSA positive
structures were similar in healthy and PE placentas. However, disruption of the syncytiotro-
phoblast layer and the presence of fibrinoids is generally observed more frequently in PE pla-
centas [14]. No correlation was found between expression of SALSA and mode of delivery. To
investigate the possible origin of AF SALSA, we performed stainings of amniotic membranes.
However, only a weak signal was observed (data not shown).
To verify the observations made by immunofluorescence microscopy and to relate SALSA
staining more precisely to tissue structures, immunoperoxidase staining was performed on par-
affin-embedded placental sections from healthy and PE placentas (Fig 3). This analysis verified
that the SALSA protein is present in fibrinoid structures in both healthy (panels A and B) and
PE (panels C and D) placentas. According to current terminology [11] fibrinoids are divided
into matrix-type fibrinoids, which are secretion products of extravillous trophoblasts, and
fibrin-type fibrinoids, which are coagulation products of maternal blood with large amounts of
fibrin. SALSA was found to be present primarily in fibrin-type fibrinoids. The staining was spe-
cifically observed within individual necrotic villous structures (Fig 3 panels A and C) and in
larger necrotic areas with massive fibrin formation (Fig 3 panels B and D). In addition, SALSA
was also seen in fibrin-type fibrinoid formations at the interfaces between placenta and
endometrium.
Expression of SALSA in early pregnancy
As shown in Fig 1, SALSA levels in the AF seem to increase during the course of pregnancy. To
get an insight into the distribution and possible role of SALSA during the development of the
placenta, sections from first trimester placentas were also included in the immunohistochemi-
cal staining (Fig 4). Fibrinoids were found to be almost absent in the first trimester placenta.
We found no staining of SALSA in the early villi. However, positive staining for SALSA was
SALSA in Pregnancy
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Fig 2. Immunofluorescencemicroscopy detection of SALSA localization in human placenta. Paraffin-embedded tissue from healthy (panels A-D) and
pre-eclamptic (PE) (panels E-F) placentas. Sections were stained with an anti-SALSA antibody (Hyb 213–06) and Alexa 546-conjugated goat anti-mouse
IgG. Red: SALSA, blue: DAPI. * denotes the center of the villus structures. M denotes the intervillous space/maternal tissue. Panels A to F show a
widespread but focal staining of SALSA in the human placenta. Based on the morphology and localization of the placental structures SALSA appears to be
present in fibrinoid formations, especially in relation to a disruption of the syncytiotrophoblast layer. (A) shows the expression of SALSA found intracellularly
in the syncytiotrophoblast layer of some, but not all, villi (white arrowhead). SALSA was observed abundantly in fibrinoid structures at the edge of the villi. A
breach of the syncytiotrophoblast layer accompanied by formation of SALSA-positive fibrinoid in the intervillous space can be observed (white arrowhead,
panel B). (C) shows SALSA in a necrotic villus with fibrinoid formation. (D) shows a villus with disrupted syncytiotrophoblast layer (white arrowhead). Here
the disruption may have led to the influx of maternal blood, and SALSA-positive fibrinoid can be observed separating the syncytiotrophoblast layer from the
underlying basement membrane. The fibrinoid may deposit all the way around the exposed villus structure, thus forming a ring structure. Syncytial damage
and fibrinoid formation is observed more frequently in PE. (E) and (F) show examples of a necrotic villus and a ring formation in PE placentas. 200×
magnifications.
doi:10.1371/journal.pone.0147867.g002
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still observed in the decidua. SALSA was present in the endothelia of maternal blood vessels.
By comparison to the endothelial marker CD34 we found that a large part of the smaller
capillaries and a portion of the larger vessels were positive for SALSA (Fig 4A–4D). The pattern
of SALSA staining in the endothelium was somewhat irregular. This could suggest that the
presence of SALSA is related to the activation status (or damage) of endothelial cells. By com-
parison to the marker cytokeratin 7, we could show that SALSA is not present in the extravil-
lous trophoblasts or uterine glands (Fig 4E and 4F). The uterine glands are thus not the source
of SALSA in the AF of early pregnancy.
Binding targets for SALSA in the placenta
So far, the results showed that SALSA was deposited in fibrin-type fibrinoids and necrotic villi
at term and irregularly on placental endothelial cells in the first trimester. To identify potential
targets for SALSA under ex vivo conditions, we performed an overlay of frozen placental sec-
tions with SALSA. Undiluted AF was used in the overlay as a source of biologically active
Fig 3. Immunohistochemistry analysis of SALSA in placenta. Paraffin-embedded placental tissue from healthy and pre-eclamptic (PE) pregnancies were
stained for SALSA. Both healthy (A) and (B) and PE (C) and (D) sections are displayed with corresponding negative IgG-controls (Neg). Based on the
morphology and location of the positively staining structures, SALSA primarily stains fibrin-type fibrinoids. (A) and (D) show staining of specific focal fibrinoid
formations in apparently necrotic villous structures. Panel B shows an example of fibrinoid “gluing” of villi. (D) shows a larger necrotic area with massive
fibrinoid formation. 200× magnifications.
doi:10.1371/journal.pone.0147867.g003
SALSA in Pregnancy
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SALSA protein (Fig 5). After addition of SALSA containing AF to the frozen placental sections,
an increase in positive staining was observed. Binding of SALSA was seen to the syncytial base-
ment membranes and the placental endothelium of most capillaries and also of larger vessels.
This indicated that targets for SALSA are present in the endothelium either directly on the sur-
face of the endothelial cells or in the extracellular matrix (ECM). The more limited focal stain-
ing observed without the overlay suggested that not only exposure of specific targets, e.g.
Fig 4. Immunohistochemical analysis of SALSA in paraffin-embedded healthy first trimester decidua. SALSA staining (A), (C) and (E) was compared
to the endothelial marker CD34 (B) and (D) and the epithelial marker cytokeratin 7 to identify uterine glands and extravillous trophoblasts (F). In the 1st
trimester decidua, SALSA was still found abundantly. However less fibrinoid structures were observed (A) and (C). Instead, SALSA was found to co-localize
with CD34 (B) and (D). The SALSA staining pattern of the endothelium is scattered, and found in both small capillaries and larger vessels. Thus, it may be
related to the activation state of the endothelium. SALSA was not found to co-localize with cytokeratin 7, and is thus not likely to be produced in the uterine
glands (E) and (F). 200× magnifications.
doi:10.1371/journal.pone.0147867.g004
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because of tissue injury, but also the availability of SALSA affects the amount of its deposition
in the tissue.
Effect of SALSA on blood clotting
The overlay results and endogenous deposition of SALSA pointed towards fibrinoids, the
ECM, disrupted syncytiotrophoblast layers and necrotic villi as targets for SALSA. SALSA has
previously been suggested to interact with fibrin/fibrinogen, platelets and erythrocytes [23].
Thus, we expected that SALSA could interact with components of the coagulation system or
the ECM. First we tested whether SALSA has any effects on blood coagulation. Blood clotting
was analyzed by measuring absorbance at 405 nm of citrated blood plasma after initiation of
coagulation by BC Thrombin reagent (Siemens). Coagulation was compared between Maxi-
sorp plate surfaces coated with or without SALSA. Fig 6 shows the clotting curve with averages
and SD’s from 5 different measurements. On both surfaces the blood clot developed at the
same speed and intensity as indicated by the increase in absorbance. Other basic coagulation
assays such as Thrombin Time and Activated Prothrombin Time measurements were also per-
formed with and without the addition of SALSA (0.5–5 μg/ml) into the plasma. Again, no effect
of SALSA was observed (data not shown).
Binding of SALSA to fibronectin
To further analyze the targets of SALSA we next investigated binding of SALSA to fibrinoid
components. As binding to fibrin has been shown previously [23], and we did not see an effect
on blood coagulation, we focused on the major fibrinoid and ECM component, fibronectin. Fig
7 shows the results of an ELISA assay where fibronectin was coated in Maxisorp wells and puri-
fied SALSA was added. A clear calcium- and dose-dependent binding was observed between
SALSA and fibronectin. Cellular fibronectin is not usually a component of fibrin-type fibrinoid,
but plasma fibronectin is. We further studied whether SALSA co-localizes with fibronectin in
placental tissues. In addition, based on the previous observations of C1q in fibrinoid structures
Fig 5. Targets for SALSA in human placenta. To determine further binding sites for SALSA in the placenta, SALSA containing AF was added as an overlay
to frozen placental sections prior to detection of SALSA by fluorescence immunohistochemistry. The addition of the SALSA containing overlay (A) revealed a
strong binding of SALSA to numerous additional structures in the placenta which were not observed without the overlay (B). SALSA binds to the endothelium
of most capillaries (Ca) and larger vessels (Ve) as well as to most of the syncytiotrophoblast layer (A). Without overlay SALSA staining is much more sporadic
or lacking in these structures (B). The strong binding after ex vivo addition of SALSA suggests that the focal staining observed in the absence of overlay (Fig
2) is a result of limited availability of SALSA rather than the lack of interacting tissue components. 400× magnifications.
doi:10.1371/journal.pone.0147867.g005
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[14], we also analyzed co-localization between SALSA and C1q. The proteins were visualized
using specific antibodies on frozen (fibronectin) or paraffin-embedded (C1q) sections. A clear
positive staining for both fibronectin and SALSA was observed (Fig 8, panels A, C and E). Inter-
estingly, fibronectin and SALSA were found in the same fibrinoid structures in partial co-locali-
zation (Fig 8 panel E, yellow color, white arrows). Most SALSA staining was seen in the inner
mass of the fibrinoid structures, while fibronectin was located at the edges of the structures. A
similar type of staining pattern was observed for SALSA and C1q (Fig 8, panels B, D and F).
When SALSA was seen deposited in necrotic villous structures or in fibrinoids, it appeared that
C1q was located on the surfaces of these. C1q seemed to encapsulate the SALSA-positive areas.
In most cases this had led to complement activation and C4 deposition (data not shown).
Discussion
The presence of SALSA in AF and its ability to regulate complement prompted us to study
SALSA in normal pregnancy and pregnancy complications. In this study we describe the
Fig 6. Analysis of the effect of SALSA on coagulation. A pool of citrated plasma was added to SALSA-
coated wells (1–5 μg/ml) and coagulation was initiated by adding BC Thrombin reagent at time point 0. The
coagulation was followed by absorbance at 405 nm and compared to coagulation in wells without SALSA
coating. We did not observe an effect of SASLA on coagulation. Displayed are averages ± SD’s from 5
different wells. A similar result was obtained when soluble SALSA (1–5 μg/ml) was added to the plasma prior
to the coagulation test (data not shown).
doi:10.1371/journal.pone.0147867.g006
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presence of SALSA and its potential targets in AF and placenta. Increased SALSA levels were
found in the first trimester AF samples from women who later developed PE. In early preg-
nancy SALSA was also found in the maternal decidual endothelium. In the placenta we found
SALSA in the syncytiotrophoblast layer and in distinct extracellular formations called
fibrinoids.
Specific findings in PE patients include maternal intravascular inflammation together with
endothelial cell activation and/or dysfunction [3,5]. In the first trimester placentas, SALSA was
present in decidua scattered in some capillaries, but not in others. The scattered staining sug-
gests that the expression of SALSA is inducible under certain conditions in the endothelium
from where it may deposit into the surrounding ECM. SALSA has not been detected in serum.
However, SALSA may be induced in close proximity and then recognize structures in the
injured endothelium or the surrounding ECM. In support of this, previous studies have dem-
onstrated up-regulation of SALSA in epithelial cells in response to several inflammatory stimuli
such as bacterial surface structures, tumor necrosis factor-α and interleukin 22 [35,36]. This is
in line with observations made in the heart tissue, where SALSA was found to be inducible in
the endothelium in pathological conditions, e.g. amyloidosis and bacterial endocarditis [23,37].
In this study we also found wide individual variation in SALSA levels in AF samples from
healthy and complicated pregnancies. No significant differences in the relative levels of SALSA
between the different disease groups were observed. In part, this may be due to the small sizes
or various subpopulations of the sample groups. In comparison to healthy controls in early
pregnancy, we did observe a trend of increased SALSA levels in AF from women who later
developed PE. In both early and late PE samples two subpopulations with high or low SALSA
levels were observed suggesting that PE patients may fall into distinct categories with regard to
a possible involvement of SALSA in the pathogenetic process. Size polymorphisms of SALSA
in AF have been described previously [27]. We tested if different variants would correlate with
the pregnancy complications studied in Fig 1, but no correlation was found (data not shown).
Both the origin and the function of SALSA in AF are still uncertain. Our study revealed, for
the first time, the presence of the SALSA protein in the placental tissue. Whether the SALSA
protein observed in the AF and in the placenta both originate from the same source remains
Fig 7. Binding of SALSA to the fibrinoid component fibronectin. Purified SALSA (1 μg/ml) was added to
Maxisorp plate wells coated with fibronectin (1–10 μg/ml) and binding was monitored using monoclonal anti-
SALSA antibodies. A clear calcium- and dose-dependent binding of SALSA to fibronectin was observed.
Averages ± SD’s from three different experiments are shown.
doi:10.1371/journal.pone.0147867.g007
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unclear. The results presented here indicate that SALSA is not produced by the uterine glands.
Amniotic membranes could be one source for SALSA in the AF. However, our observations
suggest that a possible constitutive expression there is very low (data not shown). Still, as
expected for the decidual endothelium, the expression of SALSA could be inducible. Consider-
ing the abundant secretion of SALSA from mucosal membranes, the gastrointestinal and respi-
ratory tracts of the fetus could also be sources of SALSA [27].
Fig 8. Comparison of SALSA co-localization with fibronectin and C1q. Placental sections of healthy term placentas were stained with a polyclonal anti-
fibronectin antibody (A, green) and a polyclonal anti-C1q antibody (B, green). SALSA was stained using monoclonal anti-SALSA antibody (Hyb 213–06,
panels C and D, red). Staining was visualized by immunofluorescence microscopy (200x magnifications). Superimpositions of the stainings are shown in (E)
and (F). SALSA and fibronectin are partially found in the same structures in the placenta (yellow, white arrows in panel E). SALSA is located mainly in the
inner mass of the fibrinoid structures, while fibronectin is mostly located at the edges of the structures. C1q and SALSA are also found in the same placental
structures. However, no direct co-localization was observed. Instead, C1q appears to coat the SALSA-positive fibrinoids (white arrows in panel F). 200×
magnifications.
doi:10.1371/journal.pone.0147867.g008
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SALSA has been shown to interact with other pattern recognition molecules, including both
C1q, MBL and and surfactant proteins A and D (SpA and SpD, respectively) [16,31,38]. In our
earlier study we observed wide individual variation in the levels and the protein composition of
SALSA in AF [27]. Several of the ligands of SALSA, including SpA, SpD and C1q interact with
the collectin receptor, which has been found in the amniotic epithelium [39]. It is thus possible
that SALSA in concert with these molecules affect signalling from fetal to maternal tissues.
Within the uterus SALSA may have an increasingly important role during the maturation of
the fetus towards parturition. From early pregnancy on (before 20 weeks of gestation) to term
the relative levels of SALSA doubled from 0.15‰ to 0.3‰ of the total protein amount
(p<0.05). This was matched by the observed stronger SALSA expression in term placentas.
However, whether SALSA in the AF and placenta are functionally linked remains to be
studied.
In term placentas immunohistochemical analysis showed SALSA in fibrin-type fibrinoid
structures. This type of fibrinoid is mostly composed of fibrin together with other molecules
from the coagulation system or from degenerative processes, including fibronectin [11]. The
functions of fibrinoids have so far been linked to adapting the intervillous space to the altering
flow conditions, to control the growth of the sprouting villous trees and to function as a substi-
tute barrier wherever the continuity of the syncytiotrophoblast layer at the feto-maternal inter-
face has broken down [11]. After performing several different tests to analyze the effect of
SALSA on coagulation, we did not observe an affect on the formation of the fibrin clot itself.
Instead, SALSA may be deposited after clot formation.
The lack of effect of SALSA on coagulation prompted us to search for other molecular tar-
gets in the fibrinoids. We found that SALSA bound to plasma-derived fibronectin in a dose-
and calcium-dependent manner. This finding suggests that fibronectin could be a target for
SALSA to get deposited into the fibrinoids. Fibronectin is also an ECM component, and thus
could be a target for the SALSA deposition around endothelial cells as well, as was observed in
the first trimester placentas. In term placentas we found fibronectin and SALSA in the same
fibrinoid structures in the placenta with partial co-localization. In vivo, SALSA appears to
interact with fibronectin directly. However, it is possible that other protein-protein interac-
tions, such as binding to fibrin, are also involved in the fibrinoid structures.
SALSA has previously been implied in the activation of complement [29–31]. C1q and com-
plement are known to function in the clearance of apoptotic cells and cellular debris [40]. Dys-
regulation of complement at the feto-maternal interface has for long been suspected to be part
of the etiology of PE [41]. Indeed complement activation has in many cases been observed and
recent studies found deposition of C4d on the syncytiotrophoblast layer in PE placentas [42].
No similar deposition was observed in healthy controls. In addition, our recent study described
differences in deposition of C1q and the complement inhibitor C4b binding protein in fibri-
noid structures between healthy and PE placentas [14]. SALSA has been shown to activate the
classical and lectin pathways of complement, both leading to the deposition of C4b [29–31].
We therefore also investigated co-localization of SALSA and C1q. In this study, we found com-
plement C1q deposited as a coating on the SALSA positive fibrinoids. Thus, SALSA deposition
into fibrinoids may mediate complement targeting of the necrotic fibrinoid structures in the
placenta.
SALSA was abundantly observed in areas, where the syncytial barrier between fetal and
maternal tissue had broken down. SALSA was found in fibrinoids that either replaced
destroyed syncytium, spread into the intervillous space or formed ring structures along the
basement membranes of the syncytiotrophoblast. The ring formation likely interferes with the
function of the villi by hindering the transfer of nutrients from the maternal to the fetal circula-
tion. Previous studies have indicated that both SALSA and fibronectin are involved in epithelial
SALSA in Pregnancy
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differentiation [43–46]. When the syncytium is broken the formation of fibrinoid has been
shown to be utilized by trophoblasts to re-epithelialize the villus [47]. SALSA and fibronectin
could provide an ideal scaffold for this repair process in the developing placenta.
During the development of the placenta, and especially under pathological conditions, such
as PE and other pregnancy complications, excessive placental blood flow irregularities and
damage of the syncytium may occur. SALSA could then be induced locally at the same time as
local fibrin-clot formation takes place. C1q has long been known for its housekeeping function,
targeting and assisting phagocytosis of apoptotic cells and cellular debris [48]. We therefore
suggest that in cases of local ischemia and tissue damage, the function of SALSA is to help con-
tain the necrotic process and the excessive formation of fibrinoids through interactions with
fibrin and fibronectin and thereafter participate in the targeting of C1q and complement to the
tissue debris. In addition, the SALSA-positive fibrinoid formations may function as a scaffold
for re-epithelialization of the villus.
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